Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and SRS for Melanoma or NSCLC Brain Metastases
NCT02858869Phase 1Completed
- Sponsor
- Emory University
- Start
- Oct 2016
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in melanoma, non-small cell lung cancer (NSCLC) and brain metastases (3 arms), sponsored by Emory University. Primary endpoint: Dose Limiting Toxicities at 3 months. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
melanomanon-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT02858869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858869.